(Q48744927)

15 February 2018

title

Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. (English)

1 reference

15 February 2018

beclomethasone dipropionate

1 reference

1 reference

Milgrom H

1

1 reference

15 February 2018

Biondi R

2

1 reference

15 February 2018

Georgitis JW

3

1 reference

15 February 2018

Meltzer EO

4

1 reference

15 February 2018

Munk ZM

5

1 reference

15 February 2018

Drda K

6

1 reference

15 February 2018

Wood CC

7

1 reference

15 February 2018

publication date

1 August 1999

1 reference

15 February 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

15 February 2018

volume

83

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

105-111

1 reference

15 February 2018

Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Retrospective survey of 1271 patients diagnosed as perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Ipratropium in the Treatment of Patients with Perennial Rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Intranasal ipratropium: A new treatment for perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Nebulised therapy in acute severe bronchiolitis in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Determination of dose-response reltionship for nebulized ipratropium in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Ipratropium nasal spray in children with perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Beclomethasone dipropionate aerosol in treatment of perennial allergic rhinitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Evaluation of the Multi-Test device for immediate hypersensitivity skin testing

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Comparison of the sensitivity and precision of four skin test devices

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

1 reference

7 January 2021

Behavioral side effects of medications used to treat asthma and allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Use of inhaled corticosteroids and the risk of cataracts.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

One airway, one disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962620-8

7 January 2021

10.1016/S1081-1206(10)62620-8

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018